Analysis of Clinical and Biochemical Characteristics and Left Ventricular Hypertrophy in Patients with Indeterminate Saline Infusion Test Results

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Dec 23

PMID 39713051

Authors

Huiyun Qu

Jingge Zhao

Lulu Wang

Huiyu Du

Qinghui Zhang

Tingxi Sun

Chen Zhang

Jiaxuan Chen

Linya Guo

Qi Huang

Dandan Tian

Zhilan Liu

Yibin Hao

Min Liu

Affiliations

Soon will be listed here.

Abstract

Introduction: The clinical biochemical characteristics and target organ damage (TOD) in patients with plasma aldosterone concentrations (PAC) ranging from 50 to 100 ng/L after a saline infusion test (SIT) have not been fully studied.

Methods: A total of 611 hypertensive patients with an elevated aldosterone-to-renin ratio (ARR) who underwent a supine SIT at Henan Provincial People's Hospital were enrolled. The patients were divided into three groups according to their post-SIT PAC: <50 ng/L (control group), 50-100 ng/L (indeterminate post-SIT results group), and >100 ng/L (PA group). The clinical and biochemical characteristics and TOD of the three groups were compared. The correlation of the post-SIT PAC with left ventricular mass index (LVMI) was assessed via regression analysis.

Results: The indeterminate post-SIT results group had the youngest patients and the shortest duration of hypertension. The prevalence of renal impairment (RI) and left ventricular hypertrophy (LVH) was lower than that in the PA group (P<0.05), but there was no statistically significant difference from the control group (P>0.05). After adjustment for confounders, the risk of developing carotid plaque was greater in the indeterminate post-SIT results group than in the control group (OR 1.73, 95% CI: 1.11, 2.69), and the prevalence of RI and LVH tended to increase with increasing post-SIT PAC levels. In multiple regression analyses, LVMI was significantly correlated with post-SIT PAC (P<0.05), but the basal PAC, plasma renin activity, and ARR did not significantly correlate with LVMI (P>0.05).

Conclusion: A post-SIT PAC of 50-100 ng/L may be indicative of an early form of PA, and it may serve as an independent predictor of LVH, which could be related to the level of autonomously secreted aldosterone.

References

Weigel M, Riester A, Hanslik G, Lang K, Willenberg H, Endres S . Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. Eur J Endocrinol. 2015; 172(4):443-50. DOI: 10.1530/EJE-14-1013. View

Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P . Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab. 2013; 98(4):1409-16. DOI: 10.1210/jc.2012-3353. View

Catena C, Verheyen N, Url-Michitsch M, Kraigher-Krainer E, Colussi G, Pilz S . Association of Post-Saline Load Plasma Aldosterone Levels With Left Ventricular Hypertrophy in Primary Hypertension. Am J Hypertens. 2015; 29(3):303-10. DOI: 10.1093/ajh/hpv104. View

Baudrand R, Guarda F, Fardella C, Hundemer G, Brown J, Williams G . Continuum of Renin-Independent Aldosteronism in Normotension. Hypertension. 2017; 69(5):950-956. PMC: 5391287. DOI: 10.1161/HYPERTENSIONAHA.116.08952. View

Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P . Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7(2):79-108. DOI: 10.1016/j.euje.2005.12.014. View

Hundemer G, Agharazii M, Madore F, Vaidya A, Brown J, Leung A . Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study. Circulation. 2023; 149(2):124-134. PMC: 10841691. DOI: 10.1161/CIRCULATIONAHA.123.066389. View

Liu Y, Wang M, Qiu X, Ma G, Ji M, Yang Y . A novel clinical-imaging nomogram for predicting primary aldosteronism in patients with hypertension. Hypertens Res. 2023; 46(12):2603-2612. DOI: 10.1038/s41440-023-01374-z. View

Parasiliti-Caprino M, Lopez C, Prencipe N, Lucatello B, Settanni F, Giraudo G . Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens. 2020; 38(9):1841-1848. DOI: 10.1097/HJH.0000000000002441. View

Cornu E, Steichen O, Nogueira-Silva L, Kupers E, Pagny J, Grataloup C . Suppression of Aldosterone Secretion After Recumbent Saline Infusion Does Not Exclude Lateralized Primary Aldosteronism. Hypertension. 2016; 68(4):989-94. DOI: 10.1161/HYPERTENSIONAHA.116.07214. View

10.

Lin W, Gan W, Feng P, Zhong L, Yao Z, Chen P . Online prediction model for primary aldosteronism in patients with hypertension in Chinese population: A two-center retrospective study. Front Endocrinol (Lausanne). 2022; 13:882148. PMC: 9380986. DOI: 10.3389/fendo.2022.882148. View

11.

Ohno Y, Sone M, Inagaki N, Kawashima A, Takeda Y, Yoneda T . Nadir Aldosterone Levels After Confirmatory Tests Are Correlated With Left Ventricular Hypertrophy in Primary Aldosteronism. Hypertension. 2020; 75(6):1475-1482. DOI: 10.1161/HYPERTENSIONAHA.119.14601. View

12.

Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F . Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017; 69(14):1811-1820. DOI: 10.1016/j.jacc.2017.01.052. View

13.

Fujiwara N, Haze T, Wakui H, Tamura K, Tsuiki M, Kamemura K . Differences in target organ damage between captopril challenge test-defined definitive-positive and borderline-range groups among patients with primary aldosteronism. Hypertens Res. 2024; 48(2):540-552. DOI: 10.1038/s41440-024-01943-w. View

14.

Buffolo F, Pecori A, Reincke M, Outland M, Veglio F, Schwarzlmuller P . Long-Term Follow-Up of Patients With Elevated Aldosterone-to-Renin Ratio but Negative Confirmatory Test: The Progression of Primary Aldosteronism Phenotypes. Hypertension. 2023; 81(2):340-347. DOI: 10.1161/HYPERTENSIONAHA.123.21983. View

15.

Naqvi T, Lee M . Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging. 2014; 7(10):1025-38. DOI: 10.1016/j.jcmg.2013.11.014. View

16.

Luo Q, Li N, Wang M, Yao X, Heizhati M, Zhang D . Mild primary aldosteronism (PA) followed by overt PA are possibly the most common forms of low renin hypertension: a single-center retrospective study. J Hum Hypertens. 2019; 34(9):633-640. DOI: 10.1038/s41371-019-0291-y. View

17.

Ananda R, Gwini S, Long K, Lai J, Chen G, Russell G . Diagnostic Delay and Disease Burden in Primary Aldosteronism: An International Patient Survey. Hypertension. 2023; 81(2):348-360. DOI: 10.1161/HYPERTENSIONAHA.123.21965. View

18.

Funder J, Carey R, Mantero F, Murad M, Reincke M, Shibata H . The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101(5):1889-916. DOI: 10.1210/jc.2015-4061. View

19.

Buffolo F, Monticone S, Pecori A, Pieroni J, Losano I, Cavaglia G . The spectrum of low-renin hypertension. Best Pract Res Clin Endocrinol Metab. 2020; 34(3):101399. DOI: 10.1016/j.beem.2020.101399. View

20.

Hu J, Chen X, Luo Y, Yang J, Zeng Q, Luo W . Renin-independent aldosteronism and chronic kidney disease in diabetes: Observational and Mendelian randomization analyses. Metabolism. 2023; 145:155593. DOI: 10.1016/j.metabol.2023.155593. View